105355-25-7

Basic information

• Product Name: 2-Bromo-3-[4-(2-(5-ethyl-2-pyridyl)ethoxy)phenyl]propionic acid methyl ester
• Synonyms: 2-Bromo-3-[4-(2-(5-ethyl-2-pyridyl)ethoxy)phenyl]propionic acid methyl ester;Methyl 2-bromo-3-[4-[2-(5-ethyl-2-pyridyl)ethoxy]phenyl]propionate;Methyl 2-bromo-3-(4-(2-(5-ethylpyridin-2-yl)ethoxy)phenyl)propanoate
• CAS NO: 105355-25-7
• Molecular Formula: C₁₉H₂₂BrNO₃
• Molecular Weight: 392.29
• EINECS: 1312995-182-4
• Mol File: 105355-25-7.mol
• Article Data: 6

Chemical Properties

• Boiling Point: 484.971 °C at 760 mmHg
• Flash Point: 247.102 °C
• Appearance: /
• Density: 1.309
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.568
• Storage Temp.: 2-8°C
• PKA: 5.53±0.22(Predicted)
• CAS DataBase Reference: 2-Bromo-3-[4-(2-(5-ethyl-2-pyridyl)ethoxy)phenyl]propionic acid methyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: 2-Bromo-3-[4-(2-(5-ethyl-2-pyridyl)ethoxy)phenyl]propionic acid methyl ester(105355-25-7)
• EPA Substance Registry System: 2-Bromo-3-[4-(2-(5-ethyl-2-pyridyl)ethoxy)phenyl]propionic acid methyl ester(105355-25-7)

Safety Data

• Hazardous Substances Data: 105355-25-7(Hazardous Substances Data)

Usage

General Description

"2-Bromo-3-[4-(2-(5-ethyl-2-pyridyl)ethoxy)phenyl]propionic acid methyl ester" is a complex organic compound. The name suggests that the molecule consists of a methyl ester subgroup connected to a propionic acid group, which is further substituted with a bromine atom and a phenyl ring. This phenyl ring is additionally substituted with an ethoxy group, which in turn is attached to a pyridyl ring with an ethyl group. 2-Bromo-3-[4-(2-(5-ethyl-2-pyridyl)ethoxy)phenyl]propionic acid methyl ester lies within the field of organic chemistry and its synthesis likely involves several stages, including esterification, bromination, and etherification. Its properties and uses are dependent on the actual structure and functionalities of the molecule, but they could possibly include pharmaceutical applications or uses in organic synthesis as an intermediate compound. Note that this compound may require careful handling due to the presence of a bromine atom, which could make it reactive or potentially hazardous.

InChI:InChI=1/C19H22BrNO3/c1-3-14-4-7-16(21-13-14)10-11-24-17-8-5-15(6-9-17)12-18(20)19(22)23-2/h4-9,13,18H,3,10-12H2,1-2H3

Upstream product

• 292638-85-8 acrylic acid methyl ester 
• 669716-58-9 2-[2-(4-bromophenoxy)ethyl]-5-ethyl-pyridine 
• 85583-40-0 4-[2-(5-ethylpyridin-2-yl)ethoxy]aniline 
• 350-46-9 4-Fluoronitrobenzene 
• 85583-54-6 4-[2-(5-ethyl-2-pyridyl)ethoxy]nitrobenzene 
• 5223-06-3 5-ethyl-2-(2-hydroxyethyl)pyridine 

Downstream Products

• 105355-27-9 Pioglitazone 
• 914249-67-5 pioglitazone imino ether 
• 112529-15-4 5-{4-[2-(5-ethyl-2-pyridyl)ethoxy]benzyl}-2,4-thiazolidinedione hydrochloride 
• 101931-09-3 methyl 3-{4-[2-acetoxy-2-(5-ethyl-2-pyridyl) ethoxy]phenyl}-2-bromopropionate 
• 101931-00-4 5-{4-[2-(5-ethyl-pyridin-2-yl)-2-hydroxyethoxy]benzyl}-2,4-thiazolidinedione 
• 105355-26-8 5-[[4-[2-(5-ethyl-2-pyridinyl)ethoxy]phenyl]methyl]-2-imino-4-thiazolidinone 
• 145350-19-2 methyl 2-bromo-3-{4-[2-(5-ethyl-2-pyridyl)ethoxy]phenyl}propionate N-oxide 

Relevant articles and documents

Preparation method of piogelimide

The invention provides a preparation method of piogelimide, which comprises the following steps: by using 4-[2- (5-ethyl-2-pyridyl)ethyoxyl]nitrobenzene as a starting material, methanol as a solvent and Raney Ni as a catalyst, carrying out catalytic hydrogenation, carrying out pressure filtration on the reaction solution into hydrobromic acid to carry out acidification reaction, and adding cuprousoxide, methyl acrylate and acetone into the system; dropwise adding a sodium nitrite solution, drying the organic solvent by distillation under reduced pressure after the reaction is finished, addingammonia water, alkalifying the solution by using liquid caustic soda, and extracting the product by using ethyl acetate; and adding thiourea and sodium acetate into the ethyl acetate solution, performing heating reflux until the reaction is finished, cooling the reaction product, adding water, spin-drying the reaction product, and refining the product by using DMF to obtain a piogelimide finishedproduct. According to the method, the yield and purity of the product can be effectively improved, the raw material cost is greatly reduced, the production operation is simplified, the production efficiency is improved, and the influence on the environment is greatly reduced.

Pioglitazone impurities

Methods of preparation of API pioglitazone were discussed from the point of view of impurities occurrence. Four real impurities (I-IV) of pioglitazone were prepared and characterized by means of NMR spectroscopy.

Studies on antidiabetic agents. Synthesis and hypoglycemic activity of 5-[4-(pyridylalkoxy)benzyl]-2,4-thiazolidinediones

The synthesis of a series of 5-[4-(pyridylalkoxy)benzyl]-2,4-thiazolidinediones is described. These compounds were evaluated for hypoglycemic and hypolipidemic activities in genetically obese and diabetic mice, yellow KK. 2-(2-Pyridyl)alkoxy derivatives were found to have much better hypoglycemic and hypolipidemic activities than 2-(3-pyridyl)- and 2-(4-pyridyl)alkoxy derivatives or even the previously reported compound, ciglitazone. The introduction of a hydroxyl group at the 2-position of the ethoxy chain potentiated the activities. Among the potent compounds, pioglitazone (AD-4833) was selected as a candidate compound.